Rapport TherapeuticsvsUnitedHealth

RAPP and UNH stock compared: price, dividend, valuation and results, from SEC filings.

RAPP

Rapport Therapeutics, Inc.

$23.40

Value $1.1B

-1.52%
RAPP's page

UNH

UnitedHealth Group Incorporated

$349.91

Value $318B

-10.21%
UNH's page

Rapport Therapeutics (RAPP) has a market value of $1.1B and UnitedHealth (UNH) $318B. Over the last year, with dividends, RAPP moved -6.8% and UNH +12.1%. Dividend yield: RAPP none, UNH 2.59%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    RAPP$1.1B

    UNH$318B

    UNH is 284 times RAPP

  • Revenue, 12 months

    RAPP–

    UNH$450B

  • Net income, 12 months

    RAPP-$150M

    UNH$15.9B

  • Operating margin

    RAPP–

    UNH5.3%

  • ROIC

    RAPP-20.4%

    UNH11.3%

    31.7 points apart

  • P/E

    RAPP–

    UNH20.0

  • Dividend yield

    RAPP0.0%

    UNH2.6%

    2.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

RAPP-6.8%

UNH+12.1%

100150200DecFebAprJunAugOct
Returns by period
PeriodRAPPWith dividendsUNHWith dividends
1 year since November 17, 2025-6.8%Price -6.8%+12.1%Price +9.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

RAPPRapport TherapeuticsUNHUnitedHealth

Valuation

RAPPUNH
Valuation
Price$23.40$349.91
Market value$1.1B$318B
Enterprise value (EV)$723M$363B
P/E–20.0
P/E, 5-year median–25.0
P/B2.93.1
EV/EBIT–15.2
Free cash flow yield–7.2%

Results and growth

RAPPUNH
Results and growth
Revenue, 12 months–$450B
Net income, 12 months-$150M$15.9B
Free cash flow, 12 months-$121M$22.8B
Earnings per share, 12 months-$3.16$17.52
Revenue growth, year on year–11.8%
Revenue growth a year, past–+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

RAPPUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin–5.3%
Net margin–3.5%
ROIC-20.4%11.3%
ROE-33.0%15.5%

Balance sheet

RAPPUNH
Balance sheet
Cash$395M$28.5B
Total debt$9.4M$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

RAPPUNH
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield0.0%1.8%
Shareholder yield–4.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: RAPP or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Rapport Therapeutics or UnitedHealth?

By market value, UnitedHealth ($318B) is about 284.0 times Rapport Therapeutics ($1.1B), at today's prices.

How did RAPP and UNH stock do over the last 1 years?

Since November 17, 2025, RAPP's price moved -6.8% and UNH's +9.2%. With dividends: RAPP -6.8% (-6.8% a year), UNH +12.1% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, RAPP or UNH?

The dividend yield at today's price is none for Rapport Therapeutics and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which is the better investment, Rapport Therapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.